| Autor: |
Janeni Jeevanathan, Sigrid M. Blom, Thomas Olsen, Kirsten B. Holven, Erik K. Arnesen, Torleif Trydal, Børge G. Nordestgaard, Michael Sovershaev, Ying Chen, Kjetil Retterstøl, Jacob J. Christensen |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
American Journal of Preventive Cardiology, Vol 19, Iss , Pp 100726- (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2666-6677 |
| DOI: |
10.1016/j.ajpc.2024.100726 |
| Popis: |
Background and aims: Different lipoprotein(a) [Lp(a)] assays may affect risk stratification of individuals and thus clinical decision-making. We aimed to investigate how transitioning between Lp(a) assays at a large central laboratory affected the proportion of individuals with Lp(a) result above clinical thresholds. Methods: We studied nationwide clinical laboratory data including 185,493 unique individuals (47.7 % women) aged 18-50 years with 272,463 Lp(a) measurements using Roche (2000-2009) and Siemens Lp(a) assay (2009-2019). Results: While the majority of individuals (66-75 %) had low levels of Lp(a) (50 mg/dL, 40 % more individuals with Lp(a) >100 mg/dL and 80 % more individuals with Lp(a) > 180 mg/dL than the currently used Siemens assay, likely due to calibration differences. Conclusion: Transitioning from one Lp(a) immunoassay to another had significant impact on Lp(a) results, particularly in individuals approaching clinically relevant Lp(a) thresholds. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
